CTIS2024-512023-37-00进行中（未招募）1 期
A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomy - CTOR18001GZA
GasthuisZusters Antwerpen0 个研究点目标入组 202 人开始时间: 2024年5月31日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 202
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •Male, > 18 years old, Serum albumin =3.0 g/dL, Serum creatinine <2.0 × upper limit of normal, Serum potassium =3.5 mmol/L, Serum total bilirubin =1.5 × ULN (note: in subjects with Gilbert’s syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin and if direct bilirubin is =1.5 × ULN, subject may be eligible), Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <2.5 × ULN, Medications known to lower the seizure threshold must be discontinued or substituted at least 4 weeks prior to study entry, Patient agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug., Patients who have received the information sheet and signed the informed consent form, Patients must be willing to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures, ECOG 0-1, Histologically confirmed adenocarcinoma of the prostate, Previous radical prostatectomy (RP), pT2-3, pN0 or pNx, PSA detectable with confirmed rise (at least 2 weeks apart) at least 8 weeks after RP, Hormone-naive disease, Patients amendable to take oral medication, Hemoglobin =9.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomization, Platelet count =100,000 x 109/µL independent of transfusion and/or growth factors within 3 months prior to randomization
排除标准
- •Patients with severe erectile dysfunction according to international index of erectile function (IIEF-5) questionnaire (score 1-7), Allergies, hypersensitivity or known intolerance to the study drugs or excipients., History of any of the following: Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within 1 year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect), History of any of the following: Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization, Current evidence of uncontrolled hypertension or gastrointestinal disorder affecting absorption, Patients already included in another clinical trial involving an experimental drug.
研究者
相似试验
招募中
2 期
A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomyProstate cancer2024-512023-37-00Ziekenhuis Aan De Stroom202
进行中（未招募）
1 期
A phase 2 study comparing S 95005 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated colorectal cancer who are non-eligible for intensive therapyMetastatic colorectal cancerMedDRA version: 18.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004544-18-ESaboratorios Servier S.L.154
进行中（未招募）
1 期
A phase 2 study comparing S 95005 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated colorectal cancer who are non-eligible for intensive therapyEUCTR2015-004544-18-FRInstitut de Recherches Internationales Servier150
进行中（未招募）
1 期
A phase 2 study comparing S 95005 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated colorectal cancer who are non-eligible for intensive therapyMetastatic colorectal cancerMedDRA version: 20.0 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004544-18-DEInstitut de Recherches Internationales Servier150
招募中
1 期
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPaMedDRA version: 20.0Level: PTClassification code: 10006187Term: Breast cancer Class: 100000004864Breast CancerCTIS2022-501152-28-00GBG Forschungs GmbH220